NEW YORK, June 3, 2026, 12:10 EDT
- SKIN was down roughly 3.4% in late-morning trade on the Nasdaq.
- Hydrafacial’s latest move is a June 2 update for its scalp-health treatment.
- The stock is still facing a Nasdaq minimum bid deadline of $1.
SkinHealth Systems Inc. shares moved lower Wednesday in late-morning action. The Hydrafacial parent just launched an updated scalp-health treatment aimed at bringing more users to its aesthetic-treatment platform, but the move didn’t stop the drop.
The stock slipped 2.25 cents to 64.3 cents on Nasdaq. Volume was about 336,000 shares and market value stands close to $84.5 million. SKIN remains under $1, which is the threshold needed to keep its Nasdaq listing.
HydraScalp with Keravive is out, SkinHealth announced Tuesday. The company called it a non-invasive in-office scalp treatment using Hydrafacial’s Vortex-Fusion tech and Keravive biomimetic peptides. Non-invasive means there is no surgery. SkinHealth said select Hydrafacial providers across the U.S. now have the product.
SkinHealth’s chief brand and clinical innovation officer, Whitney Cypes, said there’s a “surge in demand for scalp health.” Dermatologist Corey Hartman called the “scalp… an extension of your skin.” The company is using those talking points as it tries to push Hydrafacial outside of just facial treatments. But it’s unclear if that translates to steady clinic bookings, and that’s what investors are looking at.
SkinHealth is feeling the squeeze. The company posted first-quarter net sales of $64.9 million in its most recent quarterly filing, a drop from $69.6 million a year ago. Delivery systems sold dropped to 746 from 862. Consumables sales slipped too.
SkinHealth Systems CEO Pedro Malha described the market as “challenging” in the results, but said the “fundamentals are intact.” The company is projecting 2026 net sales of $280 million to $295 million, with adjusted EBITDA seen from $35 million to $45 million. Adjusted EBITDA removes interest, taxes, depreciation, amortization and some other items. SkinHealth Systems
Nasdaq’s warning on SkinHealth’s listing is in play. In a May filing, the company said it got notice that its shares traded under $1 for 30 business days straight, from March 26 to May 7. SkinHealth has until Nov. 4 to fix it. The closing bid, which is the quoted buying price, needs to stay at $1 or above for at least 10 straight business days to comply.
But there’s a clear risk if sales stay weak. A new product might not make up for slower device demand if clinics put off buying or people cut back on optional treatments. SkinHealth said if shares remain under $1, it may look at a reverse stock split, which would raise the share price but wouldn’t fix demand, margins, or cash flow.
Wall Street still sees SkinHealth as a Hold. Benzinga data tracked the consensus Hold call and recent moves from Roth Capital, Canaccord Genuity and TD Cowen. Roth Capital’s latest price target stayed at $2.00.
Competitive pressure looks limited. InMode, a bigger listed name in medical-aesthetics devices, was also down at midday. The weakness points to a softer tape for elective-aesthetics suppliers, not a direct read on SkinHealth’s launch.
Broader markets stayed soft. U.S. stocks fell Wednesday, with traders looking at geopolitical risk, higher oil, and new labor-market numbers. That put more pressure on smaller consumer and healthcare-device stocks.
SkinHealth faces a different test with HydraScalp now. The question is if the treatment gets enough providers returning to Hydrafacial systems to keep sales steady, as the company deals with Nasdaq’s $1 rule.
